



FONDAZIONE IRCCS  
ISTITUTO NAZIONALE DEI TUMORI

---

20133 Milano (Italy), via Venezian 1 - e-mail: medorl@istitutotumori.mi.it - fax: +39 02 2390 3353 - tel.: +39 02 2390 2150

MEDICINA ONCOLOGICA - RADIOTERAPIA

*S.S.D. Oncologia medica dei Tumori della Testa e del Collo*  
*SC Radioterapia*

## **Seminar on Nasopharyngeal cancer**

*Fondazione IRCCS Istituto Nazionale dei Tumori*

***Milan, 12 November 2015***

***Aula A***

### **Overview on molecular and radiological diagnostic and prognostic tools**

*Moderators: Dr Carlo Fallai Radiotherapy INT Milano – Dr Marco Merlano Medical Oncology H S Croce e Carle Cuneo*

- 8.15 Registration
- 9.00 Welcome: *Dr.ssa Lisa Licitra INT Milano Medical oncology*
- 9.05 NPC epidemiology in EU and in Italy: *Dr.ssa Gemma Gatta INT Milano Epidemiology*
- 9.25 Keynote lecture: EBV and NPC, screening and therapeutic opportunities: *Dr Anthony Chan Chinese University of Hong Kong Medical oncology*
- 10.00 Diagnostic, staging and FUP imaging of NPC: *Dr.ssa Giuseppina Calareso INT Milano radiology*
- 10.20 The value of EBV DNA and the need to standardize the exam
- 10.40 Prognostic factors in NPC to better tailor treatment: *Dr Paolo Bossi INT Milano Medical Oncology*
- 11.00 Q&A
- 11.10 Coffee break

**Treatment of locally-advanced cancer: how to maintain high survival rates  
and reduce treatment toxicities?**

*Moderators: Dr Mauro Palazzi H Niguarda Milano Radiotherapy – Dott. Emanuele Pignoli INT Milano  
Physics*

**Radiation oncologist point of view**

11.30 Intensity modulated radiation therapy (IMRT): the evidence of its effectiveness:

*Dr.ssa Almalina Bacigalupo IST genova Radiotherapy*

11.50 Target volumes and dose reduction: is it feasible ? *Dr Giuseppe Sanguineti IFO Roma Radiotherapy*

12. 10 **Physics point of view:** Dosimetric prognostic factors:

*Dott.ssa Anna Cavallo – Dr Alessandro Iacovelli INT Milano Radiotherapy*

12.30 **Medical oncologist point of view:** the role of chemotherapy: *Dr Daris Ferrari H S Paolo Milano  
Medical Oncology*

12.50 Late effects: how to assess and manage? QoL for NPC patients: *Dr Pierluigi Bonomo H Careggi  
Firenze Radiotherapy*

13.10 Q&A

13.15 Lunch

**Debate: treatment of locoregional recurrences, the choice between reirradiation or surgery**

*Moderators: Dr Marco Guzzo INT Milano Surgery – Dr.ssa Daniela Alterio IEO Milano Radiotherapy*

14.15 – Surgery or radiation? The need to tailor the treatment . *Prof Piero Nicolai Spedali Civili Brescia  
Surgery – Dr.ssa Ester Orlandi INT Milano Radiotherapy*

Definition of a therapeutic algorithm

Systemic and innovative treatment

14.50 Lecture: Treatment of NPC, from systemic therapies to immunotherapies : *Dr Anthony Chan Chinese  
University of Hong Kong Medical Oncology*

15.15 Results from T-cell therapy for EBV-related NPC: *Dr.ssa Simona Secondino H S Matteo Pavia Medical  
oncology*

15.35 coffee break

## **The importance of supportive care for treatment effectiveness**

Moderator: *Dr.ssa Laura Locati INT Milano Medical oncology*

16.00 Supportive care during treatment of NPC:

- Pain treatment due to disease and oncologic treatment: *Dr Paolo Bossi INT Milano MO*
- nutritional issues and dysphagia, mucositis, infection and nausea/vomiting:  
*Dr.ssa Maria Cossu Rocca IEO Milano Medical Oncology*

### **Conclusions**

- Implementation of a cooperation for clinical trials in non endemic areas
- Take home messages: the scenario of NPC treatment in the next 10 years: *Dr.ssa Lisa Licitra INT Milano Medical Oncology*

**Scientific Committee:** *Ester Orlandi Paolo Bossi Lisa Licitra*